Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria
- 19 November 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (21), 2457-2468
- https://doi.org/10.1182/blood.2020006037
Abstract
Congenital erythropoietic porphyria (CEP) is an inborn error of heme synthesis resulting from uroporphyrinogen III synthase (UROS) deficiency and the accumulation of non-physiological porphyrin isomer I metabolites. Clinical features are heterogeneous among patients with CEP but usually combine skin photosensitivity and chronic hemolytic anemia, the severity of which is related to porphyrin overload. Therapeutic options include symptomatic strategies only and are unsatisfactory. One promising approach to treating CEP is to reduce the erythroid production of porphyrins through substrate reduction therapy by inhibiting 5-aminolevulinate synthase 2 (ALAS2), the first and rate-limiting enzyme in the heme biosynthetic pathway. We efficiently reduced porphyrin accumulation after RNA interference-mediated downregulation of ALAS2 in human erythroid cellular models of CEP disease. Taking advantage of the physiological iron-dependent posttranscriptional regulation of ALAS2, we evaluated whether iron chelation with deferiprone could decrease ALAS2 expression and subsequent porphyrin production in vitro and in vivo in a CEP murine model. Treatment with deferiprone of UROS-deficient erythroid cell lines and peripheral blood CD34(+)-derived erythroid cultures from a patient with CEP inhibited iron-dependent protein ALAS2 and iron-responsive element-binding protein 2 expression and reduced porphyrin production. Furthermore, porphyrin accumulation progressively decreased in red blood cells and urine, and skin photosensitivity in CEP mice treated with deferiprone (1 or 3 mg/mL in drinking water) for 26 weeks was reversed. Hemolysis and iron overload improved upon iron chelation with full correction of anemia in CEP mice treated at the highest dose of deferiprone. Our findings highlight, in both mouse and human models, the therapeutic potential of iron restriction to modulate the phenotype in CEP.This publication has 35 references indexed in Scilit:
- Congenital erythropoietic porphyria: a single-observer clinical study of 29 casesBritish Journal of Dermatology, 2012
- A management algorithm for congenital erythropoietic porphyria derived from a study of 29 casesBritish Journal of Dermatology, 2012
- Metabolic Correction of Congenital Erythropoietic Porphyria with iPSCs Free of Reprogramming FactorsAmerican Journal of Human Genetics, 2012
- ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyriaBlood, 2011
- Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluationThe Journal of Gene Medicine, 2010
- Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type IIHuman Molecular Genetics, 2008
- Effective Gene Therapy of Mice with Congenital Erythropoietic Porphyria Is Facilitated by a Survival Advantage of Corrected Erythroid CellsAmerican Journal of Human Genetics, 2008
- A knock-in mouse model of congenital erythropoietic porphyriaGenomics, 2006
- Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivoNature Biotechnology, 2002
- Congenital erythropoietic porphyria associated with nephrotic syndrome and renal siderosisActa Paediatrica, 1995